Mitral Valve Disease Market - Global Mitral Valve Disease Industry Analysis, Size, Share, Growth, Trends and Forecast 2023-2030 -

Description

Market Overview

Mitral valve disease market size is set to surge from its current valuation of US$2.8 Bn to US$5.12 Bn by 2030. The market revenue is projected to experience a strong CAGR of 9% between 2023 and 2030.

The mitral valve disease market is experiencing significant expansion, driven by the increasing prevalence of mitral valve issues due to congenital abnormalities and infections. Congenital problems can alter the structure of the mitral valve, leading to conditions such as stenosis or regurgitation. The ageing global population also plays a critical role in the rising prevalence of mitral valve disease, thereby increasing the demand for new treatments. Despite stringent regulatory controls on the development and approval of mitral heart valves and related drugs, advancements in medical technology continue to enhance the management of mitral valve diseases.

Key Market Drivers

1. Growing Prevalence of Mitral Valve Disease: Mitral valve disease is among the most common heart valve conditions, affecting millions worldwide. According to the World Health Organization (WHO), approximately 26 million people globally suffer from mitral valve disease. The prevalence of this condition increases with age, and as the global population continues to age, the demand for effective treatments rises. Additionally, risk factors like diabetes and obesity further drive the market by increasing the incidence of mitral valve dysfunction.

2. Advancements in Technology: Innovations in medical technology and new treatment approaches have significantly improved the management of mitral valve disorders. Devices like the MitraClip, which offer a minimally invasive option for mitral valve repair, reduce mitral regurgitation and alleviate symptoms for patients who are not candidates for traditional surgery. Such technological advancements are driving the adoption of advanced treatments in the mitral valve disease market.

3. Increasing Adoption of Minimally Invasive Techniques: The demand for minimally invasive techniques for treating mitral valve disorders is growing. The development of devices like the Intrepid transcatheter mitral valve replacement (TMVR) system, which utilizes a minimally invasive transfemoral access approach, exemplifies this trend. These innovations are expected to propel market growth as they provide effective alternatives to traditional surgical procedures.

Market Challenges

1. High Costs Associated with Mitral Valve Replacement: The high cost of mitral valve replacement and repair surgeries poses a significant barrier to market growth. The cost of these procedures can vary based on factors such as disease severity, the type of procedure, and the healthcare facility. The financial burden associated with these surgeries can limit their accessibility, especially in lower-income regions.

2. Potentially Unfavorable Health Consequences: Regulatory restrictions imposed by governing bodies on the use, approval, and development of mitral heart valves and medications also hinder market growth. Strict guidelines must be followed during the production of mitral valve repair, replacement, and cardiac resynchronization devices to ensure their safety and quality. These regulations can slow down the development and commercialization of new treatments.

Emerging Trends and Opportunities

1. Growing Screening and Awareness Initiatives: Enhanced awareness campaigns, early diagnosis programs, and increased patient screening efforts are positively impacting the market. Early diagnosis by healthcare professionals improves the likelihood of successful treatments and enhances patient outcomes. Increased awareness leads to higher demand for advanced treatments, contributing to market growth.

2. Increasing Demand for Targeted Therapies and Personalized Medicine: Personalized medicine approaches, which tailor treatments based on individual patient characteristics and disease severity, have the potential to improve treatment outcomes and patient satisfaction. The integration of genetic testing and biomarker analysis into treatment decisions can optimize therapy approaches and drive market growth.

3. Expanding Presence of Key Companies: Collaborations between companies and healthcare organizations, along with exploring underserved regions for expansion, offer significant growth opportunities. Companies can increase market penetration by expanding product portfolios and distribution networks, creating a more competitive market landscape.

Regional Market Leaders

North America: North America is expected to hold the largest market share for mitral valve disease during the forecast period. The region's advanced healthcare system, increased consumer awareness, and high prevalence of mitral valve diseases contribute to this dominance. The rapid adoption of transcatheter mitral valve repair and replacement technology, along with significant improvements in minimally invasive procedures, is driving market growth in North America.

Asia-Pacific: The Asia-Pacific region is projected to experience the highest growth rate, driven by a large population base and rising purchasing power in countries like China and India. The booming pharmaceutical industry in these countries further supports this trend, making Asia-Pacific a key player in the global mitral valve disease market.

Europe: Europe also shows significant growth potential, driven by a well-established healthcare infrastructure and increased funding for the research and development of advanced treatments. European nations are focusing on developing cutting-edge medical technologies and personalized medical strategies, contributing to market growth.

In conclusion, the global mitral valve disease market is set for substantial growth, driven by the rising prevalence of mitral valve problems, technological advancements, and the increasing adoption of minimally invasive techniques. Addressing regulatory challenges and potential health risks will be crucial for sustaining growth and maximizing the market's potential.

Competitive Analysis

Abbott Laboratories
Medtronic plc
Edwards Lifesciences Corporation
Boston Scientific Corporation
LivaNova PLC
Micro Interventional Devices Inc.
XELTIS AG
Lepu Medical Technology (Beijing) Co. Ltd.
CryoLife Inc.
Colibri Heart Valve LLC
Valcare Medical
Affluent Medical
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Bayer AG

Global Mitral Valve Disease Treatment Market is Segmented as:

By Treatment Type

Mitral Valve Repair
Mitral Valve Replacement
Cardiac Resynchronization Therapy
Mitral Valve Therapeutics
- Diuretics
- Anticoagulants
- Hypertension Drugs

By Indication

Mitral Valve Stenosis
Mitral Valve Prolapse
Mitral Valve Regurgitation

By Stage

Stage C
Stage D

By End User

Hospitals
Specialty Clinics

By Geographic Coverage:

North America
- US
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Turkey
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Egypt
- Nigeria
- Rest of Middle East & Africa

1. Executive Summary

1.1. Global Mitral Valve Disease Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Disease Epidemiology
2.4. Regulatory Scenario
2.5. Technology Advancement
2.6. Disease Diagnostics Landscape
2.7. Number of procedures
- 2.7.1. Mitral Valve Repair
- 2.7.2. Mitral Valve Replacement
2.8. Value Chain Analysis
2.9. Porter's Five Forces Analysis
2.10. COVID-19 Impact Analysis
- 2.10.1. Supply
- 2.10.2. Demand
2.11. Impact of Ukraine-Russia Conflict
2.12. Economic Overview
- 2.12.1. World Economic Projections
2.13. PESTLE Analysis

3. Global Mitral Valve Disease Market Outlook, 2018 - 2030

3.1. Global Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. Mitral Valve Repair
  - 3.1.1.2. Mitral Valve Replacement
  - 3.1.1.3. Cardiac Resynchronization Therapy
  - 3.1.1.4. Mitral Valve Therapeutics
    - 3.1.1.4.1. Diuretics
    - 3.1.1.4.2. Anticoagulants
    - 3.1.1.4.3. Hypertension Drugs
3.2. Global Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 3.2.1. Key Highlights
  - 3.2.1.1. Mitral Valve Stenosis
  - 3.2.1.2. Mitral Valve Prolapse
  - 3.2.1.3. Mitral Valve Regurgitation
3.3. Global Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 3.3.1. Key Highlights
  - 3.3.1.1. Stage C
  - 3.3.1.2. Stage D
3.4. Global Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 3.4.1. Key Highlights
  - 3.4.1.1. Hospitals
  - 3.4.1.2. Specialty Clinics
3.5. Global Mitral Valve Disease Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Mitral Valve Disease Market Outlook, 2018 - 2030

4.1. North America Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Mitral Valve Repair
  - 4.1.1.2. Mitral Valve Replacement
  - 4.1.1.3. Cardiac Resynchronization Therapy
  - 4.1.1.4. Mitral Valve Therapeutics
    - 4.1.1.4.1. Diuretics
    - 4.1.1.4.2. Anticoagulants
    - 4.1.1.4.3. Hypertension Drugs
4.2. North America Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Mitral Valve Stenosis
  - 4.2.1.2. Mitral Valve Prolapse
  - 4.2.1.3. Mitral Valve Regurgitation
4.3. North America Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. Stage C
  - 4.3.1.2. Stage D
4.4. North America Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 4.4.1. Key Highlights
  - 4.4.1.1. Hospitals
  - 4.4.1.2. Specialty Clinics
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 4.5.1.2. U.S. Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 4.5.1.3. U.S. Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 4.5.1.4. U.S. Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 4.5.1.5. Canada Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 4.5.1.6. Canada Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 4.5.1.7. Canada Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 4.5.1.8. Canada Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Mitral Valve Disease Market Outlook, 2018 - 2030

5.1. Europe Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. Mitral Valve Repair
  - 5.1.1.2. Mitral Valve Replacement
  - 5.1.1.3. Cardiac Resynchronization Therapy
  - 5.1.1.4. Mitral Valve Therapeutics
    - 5.1.1.4.1. Diuretics
    - 5.1.1.4.2. Anticoagulants
    - 5.1.1.4.3. Hypertension Drugs
5.2. Europe Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Mitral Valve Stenosis
  - 5.2.1.2. Mitral Valve Prolapse
  - 5.2.1.3. Mitral Valve Regurgitation
5.3. Europe Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. Stage C
  - 5.3.1.2. Stage D
5.4. Europe Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospitals
  - 5.4.1.2. Specialty Clinics
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.2. Germany Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.3. Germany Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.4. Germany Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.5. U.K. Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.6. U.K. Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.7. U.K. Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.8. U.K. Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.9. France Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.10. France Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.11. France Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.12. France Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.13. Italy Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.14. Italy Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.15. Italy Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.16. Italy Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.17. Turkey Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.18. Turkey Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.19. Turkey Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.20. Turkey Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.21. Russia Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.22. Russia Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.23. Russia Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.24. Russia Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.5.1.25. Rest of Europe Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 5.5.1.26. Rest of Europe Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 5.5.1.27. Rest of Europe Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 5.5.1.28. Rest of Europe Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Mitral Valve Disease Market Outlook, 2018 - 2030

6.1. Asia Pacific Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 6.1.1. Key Highlights
  - 6.1.1.1. Mitral Valve Repair
  - 6.1.1.2. Mitral Valve Replacement
  - 6.1.1.3. Cardiac Resynchronization Therapy
  - 6.1.1.4. Mitral Valve Therapeutics
    - 6.1.1.4.1. Diuretics
    - 6.1.1.4.2. Anticoagulants
    - 6.1.1.4.3. Hypertension Drugs
6.2. Asia Pacific Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Mitral Valve Stenosis
  - 6.2.1.2. Mitral Valve Prolapse
  - 6.2.1.3. Mitral Valve Regurgitation
6.3. Asia Pacific Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. Stage C
  - 6.3.1.2. Stage D
6.4. Asia Pacific Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospitals
  - 6.4.1.2. Specialty Clinics
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 6.5.1. Key Highlights
  - 6.5.1.1. China Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.2. China Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.3. China Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.4. China Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.5.1.5. Japan Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.6. Japan Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.7. Japan Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.8. Japan Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.5.1.9. South Korea Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.10. South Korea Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.11. South Korea Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.12. South Korea Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.5.1.13. India Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.14. India Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.15. India Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.16. India Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.5.1.17. Southeast Asia Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.18. Southeast Asia Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.19. Southeast Asia Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.20. Southeast Asia Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.5.1.21. Rest of Asia Pacific Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 6.5.1.22. Rest of Asia Pacific Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 6.5.1.23. Rest of Asia Pacific Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 6.5.1.24. Rest of Asia Pacific Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Mitral Valve Disease Market Outlook, 2018 - 2030

7.1. Latin America Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. Mitral Valve Repair
  - 7.1.1.2. Mitral Valve Replacement
  - 7.1.1.3. Cardiac Resynchronization Therapy
  - 7.1.1.4. Mitral Valve Therapeutics
    - 7.1.1.4.1. Diuretics
    - 7.1.1.4.2. Anticoagulants
    - 7.1.1.4.3. Hypertension Drugs
7.2. Latin America Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 7.2.1. Key Highlights
  - 7.2.1.1. Mitral Valve Stenosis
  - 7.2.1.2. Mitral Valve Prolapse
  - 7.2.1.3. Mitral Valve Regurgitation
7.3. Latin America Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 7.3.1. Key Highlights
  - 7.3.1.1. Stage C
  - 7.3.1.2. Stage D
7.4. Latin America Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospitals
  - 7.4.1.2. Specialty Clinics
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 7.5.1.2. Brazil Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.3. Brazil Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 7.5.1.4. Brazil Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.5.1.5. Mexico Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 7.5.1.6. Mexico Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.7. Mexico Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 7.5.1.8. Mexico Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.5.1.9. Argentina Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 7.5.1.10. Argentina Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.11. Argentina Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 7.5.1.12. Argentina Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.5.1.13. Rest of Latin America Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 7.5.1.14. Rest of Latin America Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 7.5.1.15. Rest of Latin America Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 7.5.1.16. Rest of Latin America Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Mitral Valve Disease Market Outlook, 2018 - 2030

8.1. Middle East & Africa Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. Mitral Valve Repair
  - 8.1.1.2. Mitral Valve Replacement
  - 8.1.1.3. Cardiac Resynchronization Therapy
  - 8.1.1.4. Mitral Valve Therapeutics
    - 8.1.1.4.1. Diuretics
    - 8.1.1.4.2. Anticoagulants
    - 8.1.1.4.3. Hypertension Drugs
8.2. Middle East & Africa Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Mitral Valve Stenosis
  - 8.2.1.2. Mitral Valve Prolapse
  - 8.2.1.3. Mitral Valve Regurgitation
8.3. Middle East & Africa Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. Stage C
  - 8.3.1.2. Stage D
8.4. Middle East & Africa Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospitals
  - 8.4.1.2. Specialty Clinics
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Mitral Valve Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 8.5.1.2. GCC Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.3. GCC Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 8.5.1.4. GCC Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.5.1.5. South Africa Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 8.5.1.6. South Africa Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.7. South Africa Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 8.5.1.8. South Africa Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.5.1.9. Egypt Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 8.5.1.10. Egypt Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.11. Egypt Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 8.5.1.12. Egypt Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.5.1.13. Nigeria Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 8.5.1.14. Nigeria Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.15. Nigeria Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 8.5.1.16. Nigeria Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.5.1.17. Rest of Middle East & Africa Mitral Valve Disease Market by Treatment Type, Value (US$ Bn), 2018 - 2030
  - 8.5.1.18. Rest of Middle East & Africa Mitral Valve Disease Market by Indication, Value (US$ Bn), 2018 - 2030
  - 8.5.1.19. Rest of Middle East & Africa Mitral Valve Disease Market by Stage, Value (US$ Bn), 2018 - 2030
  - 8.5.1.20. Rest of Middle East & Africa Mitral Valve Disease Market by End User, Value (US$ Bn), 2018 - 2030
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Treatment Type vs Indication Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Abbott Laboratories
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Medtronic plc
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Edwards Lifesciences Corporation
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Boston Scientific Corporation
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. LivaNova PLC
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Micro Interventional Devices Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. XELTIS AG
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Lepu Medical Technology (Beijing) Co. Ltd.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. CryoLife Inc.
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Colibri Heart Valve LLC
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Valcare Medical
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Affluent Medical
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Teva Pharmaceutical Industries Ltd.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. Pfizer Inc.
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Product Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. Bayer AG
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Product Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations